Cambridge, UK and Indianapolis, US – 29 March 2021, 07:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces its results for the year ended 31 December 2020 and provides an update on progress with the commercialization of BARHEMSYS® and BYFAVO™ in the United States.
A presentation by Acacia Pharma’s senior management team will be webcast live today at 14.30 CEST (08.30 EST) and participants can register by clicking here or from www.acaciapharma.com. A replay will be available after the event at the same link.
International conference call dial-in details are noted below.
The results report and presentation will be available at www.acaciapharma.com in the Investors section from 07.00 CEST today.
The full Annual Report and Financial Statements will be available on the Group’s website by 31 March.
Commenting on the results, Mike Bolinder, Chief Executive Officer, said: “Our vision to become a leading US hospital pharmaceutical company is on the road to being realized. The US approval and launch in the last year of two major new products in BARHEMSYS and BYFAVO is a tremendous achievement, practically unprecedented for a company of our size.
“Our early progress on formulary adoption for BARHEMSYS reflects the unmet need that exists in PONV and strong underlying demand for our product, our outstanding and extremely experienced commercial team and salesforce, as well as our well-constructed, well-executed launch plans. During 2021, we aim to continue gaining formulary access in our initial targeted accounts, as this will lay the strong foundation for significant revenue pull-through from 2022 onwards.
“Acacia Pharma is now at an exciting stage in its path to long-term commercial success, and we intend to continue to resolutely execute our plans as we bring these important new treatments to patients and at the same time build further significant value for our shareholders. I am once again truly grateful to our employees for their dedication and remarkable efforts during this year of outstanding progress against the challenging backdrop of the COVID-19 pandemic, and to our shareholders for their continued support.”
Operating Highlights for 2020 and Significant Post-period Updates
US commercial infrastructure successfully built and fully operationalHighly experienced sales, marketing, medical affairs, commercial operations teams in placeNationwide salesforce deployed against ~900 initial targeted hospital accounts since mid-October 2020
Two high-potential products approved by the US Food and Drug Administration (FDA) in 2020BARHEMSYS (amisulpride injection)Approved February 2020 in the US with a broad label for the treatment and prevention of postoperative nausea & vomiting (PONV)First and only antiemetic approved for the rescue treatment of PONV in patients who have failed prior prophylaxisApproximately 16m surgical patients each year in the US suffer from PONV despite receiving prophylaxis1Estimated $2.7 billion annual total addressable market2BYFAVO (remimazolam injection)US commercial rights in-licensed from Cosmo Pharmaceuticals NV (“Cosmo”) in January 2020Approved July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or lessKey target: 40m procedures a year in US, including 25m gastro-intestinal procedures3Estimated >$1.5 billion annual total addressable market4
Commercialization off to excellent start, with strong early formulary uptakeAfter deploying our sales team in mid-October, to date BARHEMSYS has been added to formulary at 120 institutions – Pharmacy & Therapeutics (P&T) Committee review success > 85%Strong appreciation of clinical and health economic benefits of BARHEMSYSBYFAVO launched at end of January 2021 and in eight weeks of launch is already approved on formulary in seven accountsHigh level of enthusiasm from healthcare professionals for first major sedative launch in two decades
Management and Board ChangesGary Gemignani appointed new CFO following planned succession succeeding Christine Soden who retired as CFO and from the Board in February 2020Patrick Vink (Chairman), Pieter van der Meer and Johan Kördel stepped down from the Board of Directors at the 2020 AGMScott Byrd, a non-executive director of Acacia Pharma, was elected as Chairman at the AGM and Alessandro Della Chá, CEO of Cosmo Pharmaceuticals N.V. was appointed as a non-executive director
Named BEL Small Cap Company of the Year for the second consecutive year
Financial Highlights
Results are presented in US$, reflecting the currency of the majority of expected costs and revenues
Loss after tax for the year ended 31 December 2020 of $33.5m (2019: $22.8m):The operating loss increased by $8.5m to $30.9m (2019: $22.4m), reflecting the investment in our US commercial infrastructure and product launch preparationsR&D expenses $0.1m (2019: $3.9m) with the reduction reflecting lower R&D activities on completion of BARHEMSYS clinical program, together with a $1.4m credit on reversing certain inventory provisions on the approval of BARHEMSYSSales and marketing expenses $19.4m (2019: $14.0m) reflecting increased activities leading up to the planned launch of BARHEMSYS and BYFAVOGeneral and administrative expenses $11.6m (2019: $4.4m) with 2020 costs higher as a result of fundraising activities, staff costs and amortisation of intangibles
Cash and cash equivalents as at 31 December 2020 of $46.7m (2019: $17.0m)
Balance sheet strengthened through €20m equity investment from Cosmo, €25m loan from Cosmo, together with €25m equity financing in August 2020Additional equity financing undertaken in February 2021 with gross proceeds of €27m
Summary and Outlook for 2021
The Directors of Acacia Pharma are pleased with the excellent progress made since the beginning of 2020 in bringing two products forward to approval and now launch in the important US market. BARHEMSYS and BYFAVO are highly complementary products that together can efficiently utilize the commercial infrastructure that the Company has now built in the US.
The addition of the rights to BYFAVO along with the accompanying equity investment and debt facility from Cosmo as well as the recent equity raises have enhanced the Group’s ability to facilitate a successful launch and roll out of these products.
The early success with hospital formulary access for BARHEMSYS has confirmed the Directors’ belief in the strong product profile and compelling health economic arguments in favour of its adoption and use. This is an important first step to building a solid and growing sales platform for the product.
While it remains early days in the launch of BYFAVO, the Directors believe that it too offers significant medical and commercial value that will be viewed favorably by formulary committees and payors, as well as doctors and patients.